

(51) International Patent Classification:
A61K 47/64 (2017.01)(21) International Application Number:
PCT/US2020/063130(22) International Filing Date:
03 December 2020 (03.12.2020)

(25) Filing Language: English


(26) Publication Language: English

(30) Priority Data:
62/943,667 04 December 2019 (04.12.2019) US
62/994,791 25 March 2020 (25.03.2020) US(71) Applicant: **THE SCRIPPS RESEARCH INSTITUTE**
[US/US]; 10550 North Torrey Pines Road, La Jolla, California 92037 (US).(72) Inventors: **SHEN, Weijun**; 10550 North Torrey Pines Road, La Jolla, California 92037 (US). **SCHULTZ, Peter G.**; 10550 North Torrey Pines Road, La Jolla, California 92037 (US). **AMSO, Zaid**; 10550 North Torrey Pines Road, La Jolla, California 92037 (US).(74) Agent: **BONNEFOUS, Celine M.**; WILSON SONSINI,
650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: GLP2 RECEPTOR AGONISTS AND METHODS OF USE



(57) Abstract: Peptide conjugates comprising a peptide that modulates the GLP-2 receptor are provided. The peptide conjugates may be used for treating conditions responsive to modulation of the GLP-2 receptor. Further provided are stapled GLP-2 peptide conjugates.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*